African Cancer Genome: GMD

Summary

The goal of this study is to develop a comprehensive characterization of genetic and molecular drivers of breast and prostate cancer in individuals of African ancestry. The study is conducted by the African Caribbean Cancer Consortium (AC3) and involves the recruitment of patients from nine international AC3 research sites in the Bahamas, Barbados, Benin, Burkina Faso, Haiti, Jamaica, Kenya, Namibia, and Trinidad and Tobago, and the US. The main questions are to: molecularly characterize genomic changes in the African Cancer genomes of the breast and prostate and identify the effects of social determinants of health and lifestyle factors on mutational landscape. Black individuals that have been diagnosed with pathologically confirmed prostate or breast cancer will be included. Detailed social determinants of health survey, blood and archived FFPE tissues will be collected. (Tier 1) All patient tissues will be subject to IHC for receptor status (ER, AR, PR Her2/neu). All patients with available germline DNA from blood will receive genetic screening using a Commercial gene panel testing. (Tier 2) Patient samples with a negative genetic screening will be subject to whole exome sequencing or banked for later RNA or methylation sequencing.

Conditions

• Breast Cancer
• Prostate Cancer

Interventions

OTHER

Standard of Care

Drugs routinely administered for breast cancer per local standard.

OTHER

Standard of Care

Drugs routinely administered for prostate cancer per local standard.

Sponsors & Collaborators

• University of Miami Sylvester Comprehensive Cancer Center

  collaborator OTHER

• Pfizer

  collaborator INDUSTRY

• The University of The West Indies, Mona, Jamaica

  collaborator UNKNOWN

• Kenya Medical Research Institute

  collaborator OTHER

• University of Nairobi, Kenya

  collaborator UNKNOWN

• University of Abomey Calavi, Benin

  collaborator UNKNOWN

• Innovating Health International, Haiti

  collaborator UNKNOWN

• Institut de Recherche en Sciences de la Sante, Burkina Faso

  collaborator OTHER_GOV

• The University of the West Indies at Cave Hill, Barbados

  collaborator UNKNOWN

• The University of The West Indies School of Clinical Medicine and Research, The Bahamas

  collaborator UNKNOWN

• Ministry of Health and Social Services, Namibia

  collaborator OTHER_GOV

• Morgan State University

  collaborator OTHER

• University of Alabama, Tuscaloosa

  collaborator OTHER

• Fox Chase Cancer Center

  lead OTHER

Eligibility

Min Age

18 Years

Max Age

85 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-11-28

Primary Completion

2025-12-31

Completion

2025-12-31

Countries

• United States

Study Locations